BANZEL ORAL SUSPENSION Rx
Generic Name and Formulations:
Rufinamide 40mg/mL; orange-flavor; lactose-, gluten-, and dye-free.
Indications for BANZEL ORAL SUSPENSION:
Adjunctive treatment of seizures in Lennox-Gastaut syndrome.
Take with food in 2 equally divided doses. ≥17yrs: initially 400–800mg per day; increase by 400–800mg/day every other day up to max 3200mg/day. Avoid abrupt cessation (reduce dose by 25% every 2 days).
Take with food in 2 equally divided doses. <1yrs: not established. 1–<17yrs: initially 10mg/kg per day; increase every other day by 10mg/kg up to max 45mg/kg per day or 3200mg/day (whichever is less). Avoid abrupt cessation (reduce dose by 25% every 2 days).
Familial short QT syndrome.
Increased risk of suicidal thoughts or behavior; monitor for new or worsening of depression, suicidal thoughts, or unusual changes. Severe hepatic impairment: not recommended. Mild to moderate hepatic impairment. Dialysis (may adjust dose). Monitor for multi-organ hypersensitivity reactions; discontinue if suspected. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with drugs that shorten QT interval. CNS depression with alcohol, other CNS depressants. Antagonizes carbamazepine, lamotrigine, triazolam. May potentiate phenobarbital, phenytoin. Potentiated by valproate (reduce doses). Antagonized by carbamazepine, phenobarbital, primidone, phenytoin. May affect substrates of CYP3A4, CYP2E1 (monitor). Antagonizes hormonal contraceptives (use non-hormonal forms too). May be affected by inducers or inhibitors of carboxylesterases.
Headache, dizziness, fatigue, somnolence, nausea, incoordination, gait disturbances, ataxia, visual disturbances, leukopenia, fever/rash.
Tabs—120; Susp—460mL (w. adapter & dosing syringe)